Navigation Links
Federal Trade Commission Clears Kyphon's Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
Date:9/17/2007

SUNNYVALE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Kyphon Inc. (Nasdaq: KYPH) announced today that it has obtained clearance from the Federal Trade Commission (FTC) and U.S. Department of Justice under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended) with respect to its acquisition of the non-vertebroplasty spine-related assets and associated intellectual property rights of Disc-O-Tech Medical Technologies, Ltd., a privately held Israeli company, and its U.S. subsidiary. This clearance relates to one of two definitive agreements entered into with Disc-O-Tech in December 2006.

Completion of this acquisition, which includes the B-Twin(TM) Expandable Spinal System for use in minimally invasive fusion procedures, remains subject to obtaining approvals of antitrust authorities in other relevant jurisdictions. Kyphon expects to complete the acquisition later this year.

About Kyphon Inc.

Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose the source of low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal compression fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) (F.A.D.(TM)) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression (IPD(R)) procedure for treating the symptoms of lumbar spinal stenosis. More information about the company and its products can be found at http://www.kyphon.com and its balloon kyphoplasty patient education Web site, http://www.spinalfracture.com.

Kyphon and IPD are registered trademarks, and Functional Anaesthetic Discography and F.A.D. are trademarks, of Kyphon Inc. Disc-O-Tech, B-Twin and Confidence are trademarks of Disc-O-Tech.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, about the completion of the proposed acquisition. Forward-looking statements are based on management's current preliminary expectations and are subject to risks, uncertainties and assumptions, which may cause the company's actual results to differ materially from the statements contained herein. Factors that could cause actual results to differ materially from management's current expectations include, without limitation, the potential inability to obtain the regulatory approvals and clearances required to complete the acquisition, or to do so in a timely manner. Additional factors that may affect future results are contained in Kyphon's filings with the SEC, which are available at the SEC's website http://www.sec.gov. Kyphon undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof.

KYPHG


'/>"/>
SOURCE Kyphon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Federal bioenergy lab will give Wisconsin a chance to shine
2. Federal bill would set healthcare IT standards
3. Bill would provide federal aid for healthcare IT
4. Early Stage 10: The nuances of federal laws
5. Wisconsin can offer what a federal energy research lab needs
6. Medical technology firm lands $100K federal grant
7. New firm to help companies land federal dollars
8. Wisconsin firms urged to pursue federal SBIR dollars
9. UW-Eau Claire wins $500,000 federal science grant
10. Venture-backed firms could become eligible for federal SBIR grants
11. Federal grant-winning tips coming to Milwaukee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):